FAQ: GeoVax's Presentation at the Emerging Growth Conference on August 20, 2025
Summary
GeoVax Labs, Inc. will present updates on its GEO-MVA and Mpox vaccine development program at the Emerging Growth Conference, highlighting recent progress and regulatory advancements.
What is the main topic of GeoVax’s presentation at the Emerging Growth Conference?
The main topic is GeoVax’s GEO-MVA, a next-generation MVA-based Mpox/smallpox vaccine, and its development program, including recent progress and upcoming milestones.
Why is GeoVax’s presentation significant?
It’s significant because GeoVax recently received favorable Scientific Advice from the European Medicines Agency, potentially accelerating the regulatory approval timeline for GEO-MVA.
How can I attend the Emerging Growth Conference to hear GeoVax’s presentation?
You can register to attend the conference and receive event updates at the provided link: https://goto.webcasts.com/starthere.jsp?ei=1717088&tp_key=22f1f30884&sti=govx.
Who will be presenting on behalf of GeoVax at the conference?
David Dodd, the Company’s Chairman and CEO, will be presenting.
When is GeoVax’s presentation scheduled?
The presentation is scheduled from 3:40 PM to 3:50 PM Eastern Time on Wednesday, August 20, 2025.
What are the implications of GeoVax’s MVA platform and U.S.-based manufacturing?
These position GeoVax to address critical gaps in vaccine supply diversification, pandemic readiness, and biosecurity.
How can participants submit questions for the Q&A session?
Participants may submit questions in advance to [email protected] or ask them live during the presentation.
Will there be a replay of the presentation available after the event?
Yes, a replay will be made available on www.EmergingGrowth.com and the Emerging Growth YouTube channel.
What is GEO-MVA?
GEO-MVA is GeoVax’s next-generation MVA-based Mpox/smallpox vaccine, positioned to support global preparedness and stockpile strategies.
Who should I contact for more information about GeoVax?
For more information, you can contact the company at [email protected] or 678-384-7220, or the media contact at [email protected].
This story is based on an article that was registered on the blockchain. The original source content used for this article is located at NewMediaWire
Article Control ID: 163281